智通财经APP讯，和铂医药-B(02142)发布公告，于2025年12月5日，该公司斥资139.92万港元回购10万 股股份，每股回购价13.63-14.25港元。 ...

Group 1 - The company, Heber Pharmaceuticals-B (02142.HK), announced a share buyback on December 5, 2023, spending HKD 1.4 million to repurchase 100,000 shares [1] - The buyback price ranged from HKD 13.63 to HKD 14.25 per share [1]

呈交日期： 2025年12月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 ( ...

Core Viewpoint - The company Bai'ao Saituo has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, leveraging its "Thousand Mice and Ten Thousand Antibodies" plan and RenMice human antibody platform, but faces multiple risks including reliance on cost-cutting for profitability, high proportion of related-party transactions, patent infringement lawsuits, and significant unremedied losses [1][4]. Group 1: Financial Performance and Cost Management - From 2022 to 2024, Bai'ao Saituo's operating revenue steadily increased, with net profit turning from a loss of 602 million yuan to a profit of 33.54 million yuan, and achieving a net profit of 114 million yuan in the first three quarters of this year [6]. - However, R&D expenses significantly decreased from 699 million yuan to 324 million yuan, and the total number of R&D personnel dropped from 627 to 337, with dedicated R&D staff reduced from 58 to 5 [6]. - The revenue growth of 446 million yuan during the same period contrasts with a decline in R&D expenses of 375 million yuan, raising concerns about whether profitability improvements stem from cost-cutting rather than genuine business growth [6]. Group 2: Related-Party Transactions and Patent Litigation - The antibody development business, a key growth area for Bai'ao Saituo, has a compound annual growth rate of 58.26% from 2022 to 2024, with a gross margin exceeding 80% [7]. - Nearly 30% of the revenue in this segment comes from related parties, specifically from joint ventures such as Doma Pharmaceutical and its subsidiary, contributing a total of 170 million yuan, which accounts for 27.43% of total antibody development revenue [7]. - The core technology platform RenMice faces intellectual property risks, as a lawsuit was filed by He Bo Pharmaceutical in September 2024, alleging patent infringement, which could undermine market confidence in the company's technological independence [7]. Group 3: Unremedied Losses and Debt Concerns - As of the end of 2024, Bai'ao Saituo has accumulated unremedied losses of 1.754 billion yuan, with the company acknowledging the risk of returning to losses if R&D investments remain high or revenue growth does not meet expectations [8]. - The controlling shareholders, Shen Yuele and his wife, face significant debt obligations, needing to repay approximately 129 million yuan from 2025 to 2028, primarily relying on the liquidation of their H-shares in the company [8]. - The total compensation for the company's directors, supervisors, and key technical personnel from 2022 to 2024 reached 61.6072 million yuan, maintaining a high level despite the company's losses, which has raised inquiries from the stock exchange [8].

致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年12月4日 截至月份: 2025年11月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 頁 v 1.1.1 FF ...

Core Insights - The article emphasizes the importance of high-quality website construction as a core element for brand display, user connection, and business expansion in the digital economy [1] - It recommends ten website construction companies with core advantages, catering to enterprises of various sizes and sectors [1] Company Summaries - **Shanghai Weipai**: Established in 2017, focuses on "digital brand comprehensive services," integrating brand strategy, visual design, technical development, and digital marketing into a cohesive solution [2][5] - **Shanghai Paiqi**: Founded in 2009, has extensive experience in website construction, offering tailored solutions for both startups and mature enterprises, emphasizing a rigorous execution system [13][16] - **Shanghai Qianyan Ziji**: Specializes in lightweight technical solutions for small and medium enterprises, leveraging emerging technologies like low-code development and AI-assisted design [22] - **Pixel Flow**: Founded in 2022 in Slovakia, focuses on minimalistic design and rapid delivery for small European brands, emphasizing performance optimization [23] - **Green Pixel**: Established in 2021 in Australia, integrates sustainability into website construction, prioritizing eco-friendly practices throughout the process [24] - **Casa Digital**: Founded in 2022 in Argentina, offers localized website construction services that blend traditional visual elements with modern design for Latin American brands [25] - **Nord Code**: Established in 2022 in Norway, focuses on privacy compliance and Nordic design, providing GDPR-compliant website solutions [26] - **Afro Tech**: Founded in 2023 in Ghana, targets local SMEs with tailored digital solutions, optimizing for low bandwidth environments [27] - **Siam Design**: Established in 2023 in Thailand, combines Southeast Asian cultural elements with modern business needs in website construction [28] - **Latino Digital**: Founded in 2022 in Colombia, specializes in dynamic visual solutions for young Latin American brands, focusing on rapid iteration and engagement [29] Industry Trends - The website construction industry is evolving towards "professional segmentation and differentiated competition," with various service providers leveraging their core strengths to occupy niche markets [30]

Group 1 - The stock of Heptagon Pharmaceuticals-B (02142.HK) rose nearly 4% in the afternoon trading session, with a current increase of 3.15% at HKD 13.76 [1] - The trading volume reached HKD 33.4244 million [1]

Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has seen an increase of nearly 4%, currently trading at 13.76 HKD, following the announcement of an enhanced global strategic collaboration with AstraZeneca, focusing on the development of next-generation biotherapies including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] Group 1: Strategic Collaboration - HAPO Pharmaceutical has announced an update to its global strategic collaboration with AstraZeneca established in March 2025 [1] - The collaboration will leverage both companies' expertise to jointly discover and develop new biotherapies [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership [1] Group 2: Financial Terms - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms are consistent with the financial framework agreed upon in March 2025 [1]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Group 1: Collaboration Details - The collaboration will see AstraZeneca nominate R&D projects to Heptagon Pharmaceuticals annually over the next four years, highlighting the deepening partnership [1] - Heptagon Pharmaceuticals will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms of this collaboration align with the financial framework established in March 2025 [1] Group 2: Market Reaction - Heptagon Pharmaceuticals' stock rose nearly 4% in the afternoon session, with a current increase of 3.15%, trading at HKD 13.76, and a transaction volume of HKD 33.4244 million [1]

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 100,000 shares at a total cost of HKD 1.337 million [1] - The buyback price per share ranges from HKD 13.18 to HKD 13.53 [1]